{"version":"1.0","provider_name":"Market Newsdesk","provider_url":"https:\/\/www.marketnewsdesk.com","author_name":"Newsdesk","author_url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/","title":"Ziopharm Comments on Consent Solicitation Results - Market Newsdesk","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"BtTQiTDGZi\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ziopharm-comments-on-consent-solicitation-results\/\">Ziopharm Comments on Consent Solicitation Results<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.marketnewsdesk.com\/index.php\/ziopharm-comments-on-consent-solicitation-results\/embed\/#?secret=BtTQiTDGZi\" width=\"600\" height=\"338\" title=\"&#8220;Ziopharm Comments on Consent Solicitation Results&#8221; &#8212; Market Newsdesk\" data-secret=\"BtTQiTDGZi\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/www.marketnewsdesk.com\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","description":"Jaime Vieser and Holger Weis Elected to Board of Directors BOSTON, Dec. 16, 2020 (GLOBE NEWSWIRE) &#8212; Ziopharm Oncology, Inc. (Nasdaq: ZIOP) (\u201cZiopharm\u201d or the \u201cCompany\u201d), today issued a statement in connection with the consent solicitation (the \u201cConsent Solicitation\u201d) initiated by WaterMill Asset Management Corp., Mr. Robert W. Postma and certain other individuals (collectively, \u201cWaterMill\u201d). Based on the consents received by the Company, Jaime Vieser and Holger Weis have been formally elected to the Ziopharm Board of Directors (the \u201cBoard\u201d), while Chairman Scott Tarriff will depart the Board effective immediately. The Company\u2019s statement is as follows: \u201cWe sincerely thank our shareholders for all of the helpful feedback and constructive dialogue that they have shared with the Company since our 2020 &hellip; Continue reading \"\"","thumbnail_url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMzUwOCMzODg1MDg5IzIwMDc1NTA="}